The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Modulation of anti-tumour immunity by XPO1 inhibitors”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2026 |
Andrea Adrados, Juan Pérez-Fernández, Roberto García-Vicente, Alba Garrote-de-Barros, Joaquín Martinez-Lopez, María Linares, María Hernández-Sánchez. Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation, Frontiers in Immunology. 2026; 17: 1805129. https://doi.org/10.3389/fimmu.2026.1805129 |
|
2 |
2025 |
Kezia Gitareja, Shalini S. Chelliah, Elaine Sanij, Shahneen Sandhu, Jian Kang, Amit Khot. Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy, Cancers. 2025; 17: 2534. https://doi.org/10.3390/cancers17152534 |
|
3 |
2025 |
Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena. Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer, Cells. 2025; 14: 1991. https://doi.org/10.3390/cells14241991 |
|
4 |
2026 |
Hardany PRIMARIZKY, Satoshi KAMBAYASHI, Kenji BABA, Kenji TANI, Masaru OKUDA. Combination effect of Exportin 1 inhibitor (KPT-335) with doxorubicin or vincristine in canine lymphoma cell lines, Journal of Veterinary Medical Science. 2026; 88: 25-0478119. https://doi.org/10.1292/jvms.25-0478 |
|
5 |
2026 |
Seema Yadav, Anshul Shinde, Jyoti Rani, Ravindresh Chhabra. CRM1 as a potential biomarker and therapeutic target in cancer: a comprehensive review, The Nucleus. 2026; https://doi.org/10.1007/s13237-026-00684-0 |